We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+3.54%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.45B
AUM Growth
-$54.5M
Cap. Flow
+$154M
Cap. Flow %
10.62%
Top 10 Hldgs %
43.38%
Holding
129
New
42
Increased
32
Reduced
24
Closed
24

Top Buys

Rank Stock Value
1
LH icon
Labcorp
LH
+$37.6M
2
CYH icon
Community Health Systems
CYH
+$28.3M
3
ASND icon
Ascendis Pharma A/S
ASND
+$27.8M
4
CTLT
CATALENT, INC.
CTLT
+$23M
5
MASI
Masimo
MASI
+$18.2M

Top Sells

Rank Stock Value
1
QGEN icon
Qiagen
QGEN
+$26.7M
2
AMRN
Amarin Corp
AMRN
+$24.9M
3
OGN icon
Organon & Co
OGN
+$21.2M
4
DHR icon
Danaher
DHR
+$17.4M
5
AMN icon
AMN Healthcare
AMN
+$15.8M

Sector Composition

Rank Sector Weight
1 Healthcare 80.74%
2 Miscellaneous 17.65%
3 Industrials 1.16%
4 Financials 0.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVAX icon
76
CALL
Novavax
NVAX
$1.53B
$2.07M 0.14%
10,000
– –
EDIT icon
77
PUT
Editas Medicine
EDIT
$485M
$2.05M 0.14%
+50,000
New +$2.74M
TECX
78
Tectonic Therapeutic
TECX
$696M
$2.01M 0.14%
+29,957
New +$2.46M
GOSS icon
79
Gossamer Bio
GOSS
$83.2M
$1.88M 0.13%
+149,910
New +$1.38M
MYO icon
80
Myomo
MYO
$63.4M
$1.78M 0.12%
+150,000
New +$1.49M
ARGX icon
81
argenx
ARGX
$64B
$1.74M 0.12%
+5,746
New +$1.82M
MRTX
82
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.65M 0.11%
+9,355
New +$1.51M
IQV icon
83
IQVIA
IQV
$43.1B
$1.63M 0.11%
6,790
+1,078
+19% +$272K
LOGC
84
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$1.6M 0.11%
+349,919
New +$1.54M
ACIU icon
85
AC Immune
ACIU
$263M
$1.49M 0.1%
+221,749
New +$1.59M
DNTH icon
86
Dianthus Therapeutics
DNTH
$5.92B
$1.45M 0.1%
+12,430
New +$1.45M
ACAD icon
87
CALL
Acadia Pharmaceuticals
ACAD
$5.02B
$1.41M 0.1%
84,600
– –
ORTX
88
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$1.31M 0.09%
+56,958
New +$1.69M
AKYA
89
DELISTED
Akoya BioSciences
AKYA
$1.28M 0.09%
+91,568
New +$1.53M
RGEN icon
90
Repligen
RGEN
$9.95B
$1.27M 0.09%
4,402
+710
+19% +$182K
ASMB icon
91
Assembly Biosciences
ASMB
$694M
$1.22M 0.08%
+29,167
New +$1.22M
HSKA
92
DELISTED
Heska Corp
HSKA
$1.17M 0.08%
4,525
+1,113
+33% +$284K
AMN icon
93
AMN Healthcare
AMN
$1.34B
$1.15M 0.08%
10,000
-149,101
-94% -$15.8M
CYCN icon
94
Cyclerion Therapeutics
CYCN
$17.7M
$1.14M 0.08%
+18,598
New +$1.22M
PHAS
95
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$933K 0.06%
+300,000
New +$1M
ENSG icon
96
The Ensign Group
ENSG
$10.1B
$779K 0.05%
10,397
+1,424
+16% +$118K
ELDN icon
97
Eledon Pharmaceuticals
ELDN
$260M
$705K 0.05%
+114,008
New +$797K
MIST icon
98
Milestone Pharmaceuticals
MIST
$144M
$649K 0.04%
+113,597
New +$640K
DCPH
99
CALL
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$635K 0.04%
+18,700
New +$597K
KRRO icon
100
PUT
Korro Bio
KRRO
$190M
$479K 0.03%
1,358
-492
-27% -$194K
2 3
4
5 6

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q3 2021 Portfolio in Review

As of Q3 2021, Eversept Partners held 129 positions worth $1.45B, down 3.6% from $1.5B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Eversept Partners deployed $154M of net new capital in Q3 2021, opening 42 new positions and adding to 32 existing holdings. Its largest new stake was Labcorp: 149,354 shares worth $36.1M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 65% a quarter earlier, followed by Miscellaneous and Industrials.

On the sell side, the largest reduction was Qiagen, an estimated $26.7M trimmed.

  • Eversept Partners's largest Q3 2021 buy was Labcorp: 149,354 shares worth $36.1M.
  • Eversept Partners added most to Community Health Systems in Q3 2021, an estimated $28.3M increase.
  • Eversept Partners's biggest Q3 2021 reduction was Qiagen, cutting an estimated $26.7M.
  • Eversept Partners fully exited Organon & Co in Q3 2021, selling an estimated $21.2M.
  • Eversept Partners's ten largest holdings make up 43% of its $1.45B portfolio in Q3 2021.
  • Eversept Partners opened 42 new positions and closed 24 in Q3 2021.
  • Eversept Partners's portfolio value fell 3.6% quarter-over-quarter to $1.45B.

Based on Eversept Partners's 13F filing for Q3 2021, filed 15 Nov 2021.